The Phase 2 Trial Data In the key Phase 2 randomized controlled trial published in the New England Journal of Medicine in 2023 (N=338), participants receiving retatrutide 12 mg weekly lost a mean of 24.2% of body weight at 48 weeks versus 2.1% on placebo [1]
Monitor for signs of dehydration, poor wound healing, infection, and unexpected blood sugar swings
The neuroprotective effects of N-acetylcysteine in psychiatric and neurodegenerative disorders From modulation of glutamatergic transmission to restoration of synaptic plasticity
Ingredients: Petrolatum, Hydrogenated Polyisobutene, Polyisobutene, Phytosteryl/Isostearyl/Cetyl/Stearyl/Behenyl Dimer Dilinoleate, Butyrospermum Parkii (Shea) Butter, Diisostearyl Malate, Ethylene/Propylene/Styrene Copolymer, Sorbitan Sesquioleate, Microcrystalline Wax, Vanillyl Butyl Ether, Butylene/Ethylene/Styrene Copolymer, Ethylhexylglycerin, Water, Pentaerythrityl Tetra-di-t-butyl Hydroxyhydrocinnamate, Butylene Glycol, Melia Azadirachta Leaf Extract, Melia Azadirachta Flower Extract, Coccinia Indica Fruit Extract, Amber Powder, Mentha Piperita (Peppermint) Leaf Extract, Solanum Melongena (Eggplant) Fruit Extract, Ocimum Sanctum Leaf Extract, Curcuma Longa (Turmeric) Root Extract, Corallina Officinalis Extract, Moringa Oleifera Seed Oil, Magnesium Ascorbyl Phosphate, Citric Acid, Betaine Salicylate, Anemarrhena Asphodeloides Root Extract
